Ocuvision Biosciences-B (01477.HK) released its interim financial results, with a net loss of 132 million yuan, a year-on-year narrowing of 12.6%.

Wisdom Financial News APP News, Ocumension Bio-B (01477.HK) announced its financial performance for the six months ended June 30, 2025, with revenue of 294 million yuan, a year-on-year increase of 75.4%; a net loss of 132 million yuan, a year-on-year narrowing of 12.6%; basic loss per share of 0.17 yuan.